US drugmakers are betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

China is a one of the most important regions for the booming obesity market, thanks to government incentives and changing ...

Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

AZ's buy into the programme comes a few weeks after Regeneron published findings in the journal Science suggesting that people with certain GPR75 mutations have 54% reduced risk of obesity, based ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...